By Olivia Bugault

Merck KGaA's venture-capital arm M Ventures has been part of a 10 million euros ($10.8 million) seed round for FoRx Therapeutics, which is developing new cancer drugs.

Biotechnology company FoRx Therapeutics said Wednesday that M ventures, Novartis Venture Fund, Omega Funds, Life Sciences Partners and Pfizer Ventures participated in the funding round that is now closed.

FoRx Therapeutics is developing drugs targeting DNA replication stress for cancer, it said.

Write to Olivia Bugault at olivia.bugault@wsj.com

(END) Dow Jones Newswires

April 22, 2020 09:28 ET (13:28 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Merck KGaA (PK) Charts.
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Merck KGaA (PK) Charts.